

Noradrenaline: The forgotten neurotransmitter

Christopher B Kelly, Stephen J Cooper

Ir J Psych Med 2001; 18(1): 3-4

Depressive illness is a common and complex disorder. The biochemical hypothesis generated in the early 1960s simply postulated deficiencies of catecholamines (particularly noradrenaline (NA)) to be of aetiological importance.¹ Since that time, a multitude of other biochemical,² social³ and psychological⁴ theories have been put forward, either alone or in combination. Extension in our knowledge of cellular action has widened investigation to include 2nd messenger⁵ and even nucleic acid activity.⁶

Over the last decade, serotonin (5HT) has been and continues to be the neurotransmitter most extensively studied with respect to depressive illness. The main reason for this probably relates to the development of the selective serotonin reuptake inhibitors (SSRIs), effective antidepressants with relative specificity for the serotonergic system. More recently, the use of *in-vivo* imaging has been expanded to the study of psychiatric conditions. Ligands are currently available for some serotonergic receptors, allowing demonstration of disturbances in receptor number and activity in the brain of depressed patients.⁷

Despite the emphasis on 5HT, information continues to accrue suggesting profound disturbances in noradrenergic function in depressed patients. In the absence of an *in-vivo* marker of central noradrenergic function, researchers have continued to rely on peripheral measures such as plasma NA. There are many intervening steps between activation of the locus coeruleus, its projections and activation of sympathetic neurons. It appears simplistic to suggest that activity in one can reflect activity in the other and yet recent studies examining plasma NA spill over from the brain show a clear correlation with peripheral activity, as measured by isolated sympathetic nerve firing rate in hypertensive patients.⁸ Also, plasma NA correlates highly with cerebrospinal fluid NA in depressed patients⁹ and controls.¹⁰ Plasma NA appears to reflect central noradrenergic function.

The noradrenergic system is thought to play a key role in the normal functioning of learning, memory, attention and fear responses.¹¹ These activities have been demonstrated by a variety of experimental approaches in animals, including selective lesions; electrophysiological recording of neuronal discharge; and biochemical studies. The above physiological actions of NA suggest perturbations may be involved in the core symptoms of depression. In addition, central noradrenergic neurons have complex bi-directional

interactions with the hypothalamic-pituitary-adrenal (HPA) axis and stimulate the production of corticotrophin releasing hormone (CRH) in the hypothalamus,¹² possibly explaining the overactivity of the HPA axis in some forms of depressive illness. The sympathetic nervous system derives from brainstem noradrenergic nuclei which, with the HPA axis, are fundamentally important in the human response to stress.

There is consistent evidence that plasma NA is raised during individual episodes of melancholic or psychotic depressive illness.¹³ Also, several studies suggest that electroconvulsive therapy (ECT) reduces the plasma NA in these patients and this reduction may show a relationship with short-term improvement of depressive symptoms.^{14,15} In addition, plasma NA (measured at index episode) is one of the few biological markers known to be associated with long-term outcome; a higher index plasma NA predicting longer time to relapse; and better global outcome.¹⁶ These findings suggest that elevated plasma NA may reflect a more mutable or 'plastic' noradrenergic system, which may respond to physical treatment and be associated with a better long-term outcome. This hypothesis clearly requires further testing.

Stress is known to precipitate depressive illness.¹⁷ Although the literature linking life events and neurotransmitter function is sparse, there is considerable evidence showing that laboratory stressors can alter monoamine function. The cold pressor test (which involves immersing a hand in cold water at 4°C for two minutes) can substantially elevate plasma NA.

This elevation has been shown to be blunted in patients with depressive illness when compared to controls.¹⁸ These changes are likely to be opposed by antidepressants, though the evidence for this is mostly based on animal models.¹⁹ Changes in noradrenergic system activity may allow an integration of social, biological and treatment factors known to occur with depressive illness.

Several studies investigating noradrenergic systems in depressed patients, using different methodologies, have also found differences compared to control groups. These findings appear more frequently when investigating melancholic/psychotic patients. Urinary NA²⁰ and growth hormone responses to the alpha-adrenoceptor agonist clonidine²¹ have shown changes in depressed patients, specific to the melancholic form. Most recently, patients with treatment-resistant depressive illness have been shown to have altered cerebral venoarterial NA concentration gradients, in keeping with a deficit in brain noradrenergic function.²²

Treatment differences between subtypes of depressive illness do exist. Some recent studies have suggested a differential response between melancholic and non-melancholic depressed patients to antidepressant drugs which target the 5HT system. Melancholic patients show a better

*Christopher B Kelly, Consultant Psychiatrist, Stephen J Cooper, Consultant Psychiatrist/Senior Lecturer, Department of Mental Health, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland.

*Correspondence

SUBMITTED: JANUARY 3, 2001. ACCEPTED: FEBRUARY 9, 2001.

response to drugs which have a noradrenergic or mixed action.^{23,24} A recent meta-analysis suggests greater efficacy of broad-spectrum tricyclic antidepressants (TCAs) compared with SSRIs, for hospitalised inpatients with depressive illness.²⁵ The above findings suggest that an antidepressant's brain amine selectivity may have relevance for clinical response, at least in selected subgroups of patients with depressive illness.

Although *in vitro* selectivity for amine uptake has been clearly demonstrated between antidepressant groups, the evidence is less convincing *in vivo* in humans. The interdependence of serotonergic and noradrenergic systems has been known for many years but more recently the complex biochemical interactions of one system upon the other have been explored and incorporated into explanations of antidepressant action.²⁶ Despite these close associations, there is now clear evidence for differential physiological effects between the antidepressant classes, in platelet 5HT uptake and the pressor response to tyramine (modulated by noradrenergic systems), which mirror their *in vitro* reuptake inhibition profiles.²⁷ Such studies have become possible with the development of specific noradrenergic reuptake inhibitors (NARIs) and serotonin noradrenaline reuptake inhibitors (SNRIs).

Noradrenergic function is disrupted in depressive illness, alters with treatment and influences outcome, and, possibly, treatment response. The development of drugs with specific effects on noradrenergic systems should, as with the SSRIs, lead to greater exploration and interest in this neglected aspect of depressive illness.

References

1. Bunney WE, Davis JM. Norepinephrine in depressive reactions. *Arch Gen Psychiatry* 1965; 13: 483-93.
2. Cowen PJ, Wood AJ. Biological markers of depression. *Psychol Med* 1991; 21: 831-6.
3. Nesse RM. Is depression an adaptation. *Arch Gen Psychiat* 2000; 57: 14-20.
4. Scott J. Prevention of depression: psychological and social measures. *Advances in Psychiatric Treatment* 1995; 1: 94-101.
5. Coull MA, Lowther S, Katona CLE, Horton RW. Altered brain protein kinase C in depression: a post mortem study. *Eur Neuropsychopharmacol* 2000; 10: 283-8.
6. Veening JG, Coolen LM, Spooren WJ et al. Patterns of c-fos expression induced by fluvoxamine are different after acute versus chronic oral administration. *Eur Neuropsychopharmacol* 1998; 8: 213-26.


7. Sargent PA, Kjaer KH, Bench CJ et al. Brain serotonin 1A receptor binding measured by positron emission tomography with [¹¹C] WAY-100635: effects of depression and antidepressant treatment. *Arch Gen Psychiat* 2000; 57: 174-80.
8. Esler MD, Lambert GW, Ferrer C et al. Central nervous system noradrenergic control of sympathetic outflow in normotensive and hypertensive humans. *Clin Exp Hypertens* 1995; 17: 409-23.
9. Roy A, Pickar D, De Jong J et al. Norepinephrine and its metabolites in cerebrospinal fluid, plasma and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression. *Arch Gen Psychiat* 1988; 45: 849-57.
10. Ziegler MG, Lake CR, Wood JH, Brooks BR, Ebert MH. Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood cerebrospinal fluid barrier for norepinephrine. *J Neurochem* 1977; 28: 677-9.
11. Fillenz M. Noradrenergic neurons 1st Ed. Cambridge: Cambridge University Press 1990; 206-28.
12. Brady LS. Stress, antidepressant drugs and the locus coeruleus. *Brain Res Bull* 1994; 35: 545-56.
13. Kelly CB, Cooper SJ. Differences and variability in plasma noradrenaline between depressive and anxiety disorders. *J Psychopharmacol* 1998; 12: 161-7.
14. Kelly CB, Cooper SJ. Plasma noradrenaline response to electroconvulsive therapy in depressive illness. *Br J Psychiat* 1997; 171: 182-6.
15. Werstiuk ES, Coote M, Griffith L, Shannon H, Steiner M. Effects of electroconvulsive therapy on peripheral adrenoceptors, plasma noradrenaline, MHPG and cortisol in depressed patients. *Br J Psychiat* 1996; 169: 758-65.
16. Johnston TG, Kelly CB, Stevenson M R, Cooper SJ. Plasma norepinephrine and prediction of outcome in major depressive disorder. *Biol Psychiat* 1999; 46: 1253-8.
17. Fava GA, Munari F, Pavan L, Kellner R. Life events and depression. A replication. *J Affect Disord* 1981; 3: 159-65.
18. Kelly CB, Cooper SJ. Plasma norepinephrine response to a cold pressor test in subtypes of depressive illness. *Psychiatry Res* 1998; 81: 39-50.
19. Anisman H, Zacharko RM. Depression: the predisposing influence of stress. *Behav Brain Sci* 1982; 5: 89-137.
20. Maes M, Vandewoude M, Schotte C, Blockx P. Positive relationship between the catecholaminergic turnover and the DST results in depression. *Psychol Med* 1990; 20: 493-9.
21. Checkley SA, Glass IB, Thompson C, Corn T, Robinson P. The GH response to clonidine in endogenous as compared with reactive depression. *Psychol Med* 1984; 14: 773-7.
22. Lambert G, Johansson M, Agren H, Friberg P. Reduced brain norepinephrine and dopamine release in treatment - refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. *Arch Gen Psychiatry* 2000; 57: 787-93.
23. Danish University Antidepressant Group. Paroxetine a selective serotonin uptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicentre study. *J Affect Disord* 1990; 18: 289-99.
24. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. *Am J Psychiat* 1994; 151: 1735-9.
25. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. *J Affect Disord* 2000; 58: 19-36.
26. Davis R, Wilde MI. Mirtazepine: a review of its pharmacology and therapeutic potential in the management of major depression. *CNS Drugs* 1996; 5: 389-402.
27. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. *Arch Gen Psychiat* 2000; 57: 503-9.

The Irish Journal of
Psychological Medicine
welcomes all correspondence by Email

Email us at:

psychological@medmedia.ie

You made her life more complete...



SEROXAT

PAROXETINE



Simple. Proven. Lifts depression. Calms anxiety.

PRESCRIBING INFORMATION Presentation: 'Seroxat' Tablets, PA 49/50/1-2, each containing either 20 mg or 30 mg paroxetine as the hydrochloride and 'Seroxat' Liquid, PA 49/50/3, containing 20 mg/10ml paroxetine as the hydrochloride. **Uses:** Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Prevention of relapse and also recurrence of further depressive episodes. Treatment of symptoms and prevention of relapse of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of panic disorder with or without agoraphobia. **Dosage:** Adults: Depression: 20 mg daily and if necessary increase dose by 10 mg increments to a maximum of 50 mg according to response. Obsessive compulsive disorder and panic disorder: 40 mg daily. Start on 20 mg and increase weekly in 10 mg increments to a maximum of 60 mg daily according to response. Possible worsening of panic symptoms during early treatment of panic disorder is generally recognised, thus low initial starting dose is recommended. Dosage should be reviewed and adjusted if necessary within two to three weeks of initiation of therapy and thereafter as judged clinically appropriate. Continue treatment for a sufficient period, which may be several months for depression and for OCD and may be even longer (9 months) for panic disorder. Abrupt discontinuation should be avoided. **Elderly:** 20 mg daily increasing by increments of 10 mg up to 40 mg daily according to response. **Children:** Not recommended. Severe renal impairment (creatinine clearance <30 ml/min) or severe hepatic impairment: 20 mg daily. Restrict incremental dosage if required to lower end of range. **Contra-indications:** Hypersensitivity to paroxetine and related drugs; use with MAO inhibitors; unstable epilepsy or convulsant disorders; severe renal failure. **Precautions:** History of mania. Cardiac conditions, use with ECT: caution. Caution in patients with controlled epilepsy (monitor carefully). Stop treatment if seizures develop. Caution patients about driving and operating machinery. **Drug interactions:** Do not use with or within two weeks after stopping MAO inhibitors; leave a two-week gap between stopping 'Seroxat' and before starting MAO inhibitor treatment. Possibility of interaction with tryptophan. Great caution with warfarin and other oral anticoagulants. Consider using lower doses if given with drug metabolising enzyme inhibitors; adjust 'Seroxat' dosage if necessary when given with drug metabolising enzyme inducers. Combination with other highly bound protein drugs may alter plasma levels of either. Alcohol is not advised. Caution with other CNS active drugs. Keep dosage of concomitant benzodiazepines low. Use concurrent lithium administration with caution and monitor lithium levels. **Pregnancy and lactation:** Use in pregnancy only if essential and avoid during lactation. **Adverse reactions:** Most commonly nausea, somnolence, sweating, tremor, asthenia, dry mouth, insomnia, sexual dysfunction (impotence and abnormal ejaculation), hyperprolactinaemia/galactorrhoea, dizziness, constipation, diarrhoea, decreased appetite. Spontaneous reports of dizziness, headache, acute glaucoma, vomiting, diarrhoea, restlessness, hallucinations, hypomania, rash, blurred vision. Rarely mania has been reported. As with other SSRIs, symptoms suggestive of postural hypotension, hypotension, hypertension, tachycardia. Also other arrhythmias (rare). Extrapyramidal reactions, rarely hyponatraemia (possible SIADH), liver function abnormality. Abrupt discontinuation may cause dizziness, sensory disturbance, agitation or anxiety, nausea and sweating. **Product authorisation holder:** GlaxoSmithKline, Carrig Avenue, Dun Laoghaire, Co. Dublin. **Further information is available from this address.** Telephone: 01-284 5555. November 2000. 'Seroxat' is a trade mark. © 2001 GlaxoSmithKline.

 GlaxoSmithKline

Free Seroxat jigsaw available on request, while stocks last. Tel. 01 214 7784.